Videos

Daniel Pilch, PhD, discusses the approach that he and his team took to develop a new drug to fight MRSA.

Kenneth Mayer, MD, discusses some societal challenges that at-risk individuals face today that may keep them from taking pre-exposure prophylaxis.

Milena McLaughlin, PharmD, MSc, explains how antimicrobial shortages differ between high- and low-income countries.

Edmond LaVoie, PhD, describes the properties of prodrug TXA709.

Daniel Pilch, PhD, discusses the potential of Staphylococcus aureus to develop resistance to TXA709.

Jessica Justman, MD, explains the PHIA Project (population-based HIV impact assessments).

Meghan Jeffres, PharmD, discusses the legal liability of prescribing beta-lactams to patients who are allergic to penicillin.

ason Gallagher, PharmD, BCPS FCCP, FIDSA, explains why clinicians should be aware of the challenges associated with getting antimicrobial susceptibility testing results.

Arjun Srinivasan, MD, discusses how outbreaks can occur in operating rooms.

Hanneke Schuitemaker, PhD, explains what makes Janssen’s new HIV-1 vaccine regimen unique.

Milena McLaughlin, PharmD, MSc, explains ways to remain vigilant when it comes to drug shortages.

Elizabeth Phillips, MD, FRCPC, FRACP, addresses the misconceptions about penicillin allergies.

Meghan Jeffres, PharmD, discusses the utility of penicillin skin testing for patients labeled as penicillin allergic.

Alex Rinehart, PhD, Director, Global Prevention Strategy, ViiV Healthcare, explains what makes cabotegravir a unique medication for HIV.

Kenneth Mayer, MD, explains why primary care providers need to have a good sense of their patients in order to help them decide if PrEP is right for them.

Benjamin Young, MD, PhD, discusses the four partners behind the Fast-Track Cities Initiative.

Snigdha Vallabhaneni, MD, MPH, shares actions patients and their visitors can take to protect themselves from Candida auris.

Pedro Cahn, MD, explains the new formulation of raltegravir HD.

Kathleen Squires, MD, explains how HIV treatment has changed since the 1980s.

Lynne Mofenson, MD, shares an update on the health burden of mother-to-child transmission (MTCT) of HIV.

Jake Glaser discusses how generating interest for the response to HIV and AIDS has changed since the 1990s.

Peter Williams, PhD, discusses the LATTE-2 trial for HIV treatment.

Magda Opsomer, MD, explains why darunavir may be more beneficial than other HIV medications.

Ariane van der Straten, PhD, MPH, explains the different attributes of administering pre-exposure prophylaxis via a HIV biomedical implant.

Leah Johnson, PhD, discusses the biomedical HIV prevention implant that is being developed by RTI International.

Kenneth Mayer, MD, explains why tenofovir alafenamide may be the future of pre-exposure prophylaxis.

Arjun Srinivasan, MD, stresses the importance of surgical teams speaking up if they have safety concerns regarding procedure in operating rooms.

Jason Pogue, PharmD, BCPS-ID, explains his team’s study regarding the susceptibility of Pseudomonas isolates to ceftolozane/tazobactam.